Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD) (NMOSD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Wei Yiming
- Phone Number: +8615652385796
- Email: 982210496@qq.com
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China, 361000
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Jianpeng Li
- Phone Number: +86 13860192261
- Email: 806469536@qq.com
-
Xiamen, Fujian, China, 361000
- Zhongshan Hospital Xiamen University
-
Contact:
- Xingyu Chen
- Phone Number: +86 136 0090 4488
- Email: 2005chenxingyu@163.com
-
Xiamen, Fujian, China, 361000
- The Second Affiliated Hospital of Xiamen Medical College
-
Contact:
- Ruiqiang Peng
- Phone Number: +86 15880297185
- Email: hbprq@163.com
-
Xiamen, Fujian, China, 361000
- Xiamen Hospital of Traditional Chinese Medicine
-
Contact:
- Wei Yiming
- Phone Number: +8615652385796
- Email: 982210496@qq.com
-
Xiamen, Fujian, China, 361000
- Zhongshan Hospital (Xiamen), Fudan University
-
Contact:
- Guoqiang Fei
- Phone Number: +86 13681973572
- Email: fei.guoqiang@zs-hospital.sh.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria Inclusion Criteria for the NMOSD Patient Group
- Aged 18 years or older, regardless of sex
- Fulfilled the diagnostic criteria for Neuromyelitis Optica Spectrum Disorders as defined by the 2021 Chinese guidelines for the diagnosis and management of NMOSD
- Seropositive for AQP4-IgG
- Provided informed consent by the participant or their legal guardian
Inclusion Criteria for the Healthy Control Group
- Aged 18 years or older, regardless of sex
- Gender- and age-matched healthy individuals
- Provided informed consent by the participant or their legal guardian
Exclusion Criteria
- Diagnosis of other serious systemic diseases (e.g., malignancy)
- Presence of severe psychiatric disorders that would preclude compliance with study procedures and/or follow-up assessments
- History of infectious pathologies of the central nervous system
- Those with severe liver and kidney function impairment or dysfunction of other vital organs
- Patients with other conditions that do not allow participation in clinical research
- Patients allergic to gadolinium-DPTA
- Patients with other conditions that do not allow participation in clinical research
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
MNOSD patient group
The NMOSD patient cohort consisted of adults (≥18 years) who met the 2021 Chinese diagnostic criteria, were AQP4-IgG seropositive, and provided informed consent.
|
This study will explore and validate the characteristics of sex hormone levels in MNMOSD
This study will explore the comparison of sex hormone levels between a healthy control group and MNMOSD
|
|
Healthy control group
Age- and sex-matched healthy controls (≥18 years) who provided informed consent
|
This study will explore and validate the characteristics of sex hormone levels in MNMOSD
This study will explore the comparison of sex hormone levels between a healthy control group and MNMOSD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Variations in Serum Sex Hormones
Time Frame: Baseline, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months.
|
Baseline, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Shiyong Li, Xiamen Hospital of Traditional Chinese Medicine
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2025-K065-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.